Impact of diagnosis‐to‐ablation time on clinical outcomes in patients with early‐onset atrial fibrillation

Abstract Background Evidence was lacking for the early choice of radiofrequency ablation (RFA) among patients with early‐onset atrial fibrillation (AF). Hypothesis This study aimed to explore whether earlier RFA was associated with better clinical outcomes among early‐onset AF patients. Methods Patients, who were diagnosed with AF before 45 years and underwent their first RFA procedures at baseline of the China Atrial Fibrillation registry, were enrolled and divided into four diagnosis‐to‐ablation time (DAT) groups: DAT ≤ 1 year, 1 year < DAT ≤ 3 years, 3 years < DAT ≤ 6 years, and DAT > 6 years. Another group of nonablation patients, who were newly diagnosed with AF and younger than 45 years, were also included. Adjusted associations of groups with composite cardiovascular events (cardiovascular death, embolism, major hemorrhages, or cardiac rehospitalization) or recurrent AF were analyzed using Cox proportional hazards models. Results Among 1694 patients who underwent their first RFA at enrollment, incidences of composite cardiovascular outcomes were increasing with extension of DAT (DAT ≤ 1 year: 6.1/100 person‐years, 1 year < DAT ≤ 3 years: 7.9/100 person‐years, 3 years < DAT ≤ 6 years: 7.6/100 person‐years, DAT > 6 years: 10.5/100 person‐years; p < .001). In comparison with DAT > 6 years group, the DAT ≤ 1 year group was associated with reduced risk of cardiovascular events (adjusted hazard ratio, HR [95% confidence interval, CI] = 0.64 [0.47–0.87], p = .005) and AF recurrence (adjusted HR [95% CI] = 0.70 [0.57–0.88], p = .002). Associations remained similar after stratified by AF types. Compared to nonablation group ( n = 413), DAT ≤ 1year patients tended to show lower cardiovascular risk (adjusted HR [95% CI] = 0.78 [0.58–1.05], p = .099) and lower risk of recurrent AF (adjusted HR [95% CI] = 0.46 [0.38–0.55], p < .001). Conclusions A shorter DAT was associated with a lower risk of cardiovascular events and recurrent AF for early‐onset AF patients.